Business Wire

QUECTEL-WIRELESS

26.6.2024 13:01:27 CEST | Business Wire | Press release

Share
Quectel Unveils FLM263D Wi-Fi Module: Pioneering Seamless Connectivity with ACK SDK for Matter

Quectel Wireless Solutions, a global IoT solutions provider, announced the launch of the FLM263D standalone Wi-Fi module that supports Alexa Connect Kit (ACK) SDK for Matter, enabling IoT devices to connect seamlessly with Matter compliant controllers including Amazon Alexa, Google Home, Samsung SmartThings, and Apple HomeKit.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626747648/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel unveils FLM263D Wi-Fi module: Pioneering seamless connectivity with ACK SDK for Matter (Photo: Business Wire)

Matter stands as a pivotal standard in smart home communication, tackling the persistent challenges of compatibility and fragmentation within the sector by enabling direct communication between smart devices. Governed by the Connectivity Standards Alliance (CSA), Matter devices undergo a stringent certification process to ensure secure, reliable, and universally interoperable connections. Adherence to this certification is paramount for all Matter-compliant products, fostering a unified communication framework and enhancing user experiences.

“We created ACK to make it simpler for device makers to build smart home devices with a fully-managed service without having deep expertise in multiple wireless protocols, complex cloud connectivity, and the necessary maintenance of cloud infrastructure. We are excited about this launch because Quectel’s FLM263D adds to ACK's portfolio of available solutions and offers more choices for device makers,” says Ben McInnis, Director, Smart Home, Amazon.

“Revolutionizing connectivity in the smart home landscape, our latest FLM263D module sets a new standard for seamless integration,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “It also empowers developers with robust support for the ACK SDK for Matter, ensuring unparalleled interoperability and innovation in the IoT ecosystem.”

The FLM263D module is a 2.4GHz single band Wi-Fi 6 module, featuring a high-performance processor with a frequency of up to 320MHz. This innovative module boasts support for IEEE 802.11b/g/n/ax protocol and BLE 5.2, paired with built-in 512KB SRAM and 4MB flash for optimal performance. Furthermore, it meets rigorous security standards, including secure boot and mbed TLS encryption, ensuring robust protection for connected devices.

The FLM263D offers support for device certifications such as Works with Alexa (WWA) and features such as Matter Simple Setup (MSS). MSS allows end-users to seamlessly connect Matter-compliant smart home devices to Alexa with zero-touch setup, while WWA instils consumer confidence when buying on Amazon.

FLM263D offers five GPIO interfaces that can alternatively function as PWM or I2C communication channels. Designed with an LCC form factor, built-in PCB antenna, measuring a mere 17.3mm × 15.0mm × 2.8mm, and with an operating temperature range of -40°C to +105°C, 3.0~3.6V power supply, the FLM263D is perfectly suited for smart lighting applications, especially smart bulbs.

Additional modules will be rolled out very soon to expand the scope of Quectel offerings to include smart switches, smart plugs, and other smart household applications.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240626747648/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye